ALK and anaplastic large cell lymphoma: Furthermore, FOXM1 may be a potential therapeutic target in ALK + ALCL, and disruption of the binding between FOXM1 and NPM1 in the NPM-ALK—NPM1 heterodimers may serve as a highly specific anti-cancer therapeutic approach for NPM-ALK + ALCL.